Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
Amy S. Paller, Lisa A. Beck, Andrew Blauvelt, et al.
Pediatric Dermatology (2022) Vol. 39, Iss. 2, pp. 187-196
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, et al.
The Lancet (2022) Vol. 400, Iss. 10356, pp. 908-919
Closed Access | Times Cited: 177
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
El‐Bdaoui Haddad, Sonya Cyr, Kazuhiko Arima, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 7, pp. 1501-1533
Open Access | Times Cited: 45
Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
Eric L. Simpson, Patrick M. Schlievert, Takeshi Yoshida, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 5, pp. 1179-1195
Open Access | Times Cited: 41
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
Sneha Butala, Leslie Castelo‐Soccio, Rishi Seshadri, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 5, pp. 1361-1373
Open Access | Times Cited: 21
Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis
Jan Hartmann, Lucas Moitinho‐Silva, Nicole Sander, et al.
Allergy (2023) Vol. 78, Iss. 8, pp. 2290-2300
Open Access | Times Cited: 19
Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification
Claudia Hülpüsch, Robin Rohayem, Matthias Reiger, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 31-41
Closed Access | Times Cited: 7
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 2, pp. 163-173
Open Access | Times Cited: 6
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab
Andrew Blauvelt, Andreas Wollenberg, Lawrence F. Eichenfield, et al.
Advances in Therapy (2022) Vol. 40, Iss. 1, pp. 367-380
Open Access | Times Cited: 19
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Maddalena Napolitano, Maria Esposito, Maria Concetta Fargnoli, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis
Rose Alraddadi, Mulham Kalantan, Yara Aljefri, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDISTAD
Amy S. Paller, Marjolein de Bruin‐Weller, Danielle Marcoux, et al.
Journal of the American Academy of Dermatology (2024)
Open Access | Times Cited: 3
Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)
Victor Pera, Guy Brusselle, Sebastian Riemann, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis – a meta-analysis of randomized clinical trials
Monika Marko, Rafał Pawliczak
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 1, pp. 121-134
Closed Access | Times Cited: 7
A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up
Jennifer Clay Cather, Melodie Young, Douglas C. DiRuggiero, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 9, pp. 2013-2038
Open Access | Times Cited: 11
Therapeutical Targets in Allergic Inflammation
Lorenzo Salvati, Francesco Liotta, Francesco Annunziato, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2874-2874
Open Access | Times Cited: 11
Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Gil Yosipovitch, Brian Kim, Shawn G. Kwatra, et al.
JAAD International (2024) Vol. 16, pp. 163-174
Open Access | Times Cited: 2
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
An updated reappraisal of dupilumab in children and adolescents with moderate–severe atopic dermatitis
Giorgio Ciprandi, Amelia Licari, Maria Angela Tosca, et al.
Pediatric Allergy and Immunology (2024) Vol. 35, Iss. 6
Closed Access | Times Cited: 2
New Concepts in Barrier Dysfunction in CRSwNP and Emerging Roles of Tezepelumab and Dupilumab
Simon Chiang, Stella E. Lee
American Journal of Rhinology and Allergy (2023) Vol. 37, Iss. 2, pp. 193-197
Closed Access | Times Cited: 5
Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement
Carmela Giancotta, Nicole Colantoni, Lucia Pacillo, et al.
Frontiers in Pediatrics (2023) Vol. 11
Open Access | Times Cited: 5
Dupilumab: Two sides of a side‐effect
Peter H. Hoeger
Pediatric Dermatology (2024) Vol. 41, Iss. 1, pp. 180-181
Closed Access | Times Cited: 1
Ramsay Hunt syndrome in atopic dermatitis patient treated with dupilumab
Jarmila Čelakovská, Petra Boudková, Veronika Wertzová, et al.
International Immunopharmacology (2024) Vol. 136, pp. 112345-112345
Closed Access | Times Cited: 1
Unveiling the value of C‐reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross‐sectional study
L. Quintana‐Castanedo, Silvia Sánchez‐Ramón, R. Maseda, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 8
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top